| Date | Title | Description |
| 14.11.2022 | Всё о провалах стартапов: причины, стадии, лучшие отрасли и страны | Давно известная и не меняющаяся статистика: 9 из 10 стартапов «умирают» и закрываются. Почему проекты success story случается не всегда? В каких отраслях выше вероятность «выжить» и в каких странах — лучшая статистика успешных стартапов? Мы... |
| 29.09.2022 | Pfizer Pours in Almost $120 million for App that Detects Covid from Cough | Joaquin Victor Tacla, Tech Times 29 September 2022, 06:09 am
Pfizer recently paid over US$120 million to acquire a small Australian firm that claims to have created a smartphone app that can accurately detect COVID-19 by listening to cough,... |
| 12.04.2022 | Pfizer bids $100 million to acquire Australian COVID-19 testing startup | Source: Unsplash/CDC.
Global pharmaceutical giant Pfizer has made a $100 million bid to acquire eight-year-old Australian diagnostic technology company ResApp, as HealthTech continues to attract attention amid the ongoing pandemic.
The Bris... |
| 22.03.2022 | Detecting COVID-19 using only a smartphone | 92% sensitivity for detecting COVID-19 with a new cough audio-based algorithm
BRISBANE, Australia, March 22, 2022 /PRNewswire/ -- ResApp Health Limited (ASX:RAP) today announced positive results for a new novel cough audio-based COVID-19 sc... |
| 03.02.2022 | ResApp Health : Cough analysis patent granted in China | View printer-friendly version
Brisbane, Australia, 1 February 2022 - ResApp Health Limited (ASX:RAP), a leading digital health company developing smartphone applications for the diagnosis and management of respiratory disease, today announc... |
| 22.12.2021 | ResApp Health : Distribution agreement with Sanrai International for emerging markets | View printer-friendly version
Sanrai International appointed to promote, market and sell ResAppDx in emerging markets
Sanrai is a distributor of innovative medical device products to emerging markets and has long-standing relationships in m... |
| 20.12.2021 | ResApp Health : receives $818,826 in R&D tax incentive refund | View printer-friendly version
Brisbane, Australia, 20 December 2021 - ResApp Health Limited (ASX:RAP), a leading digital health company developing smartphone applications for the diagnosis and management of respiratory disease, is pleased t... |
| 30.11.2021 | ResApp Health : receives world's first regulatory approvals for cough counter smartphone application | View printer-friendly version
Smartphone-only cough counter application approved as a medical device in Australia and Europe
Technology already in use by a global pharmaceutical company to monitor disease in a clinical trial
Discussions on-... |
| 19.11.2021 | ResApp Health : New publication highlights challenges of diagnosing acute respiratory disease in emergency departments | View printer-friendly version
The first known evaluation of diagnostic accuracy by emergency department clinicians for acute respiratory disease
The authors found that acute paediatric respiratory disease was frequently misdiagnosed, with o... |
| 18.11.2021 | ResApp Health : secures contract with global pharmaceutical company | View printer-friendly version
ResApp has signed a licensing agreement with Janssen Pharmaceutica NV, one of the Janssen Pharmaceutical Companies of Johnson & Johnson, to use ResAppDx technology in an RSV clinical trial
First time ResApp... |
| 17.11.2021 | ResApp Health : Partnership with Carepath for passive in-home monitoring of COPD patients | View printer-friendly version
Carepath is a Berlin-based company developing a telehealth platform that passively monitors patients in residential environments
Carepath's hardware-software platform, NELA, is designed to monitor and measure s... |
| 26.10.2021 | ResApp Health : COVID-19 Clinical Studies Update | View printer-friendly version
Completed recruitment of 100 positive COVID-19 cases in India
Indian study expanded to 200 positive COVID-19 cases and scheduled to complete recruitment by end of November 2021
US recruitment expected to comple... |
| 11.10.2021 | ResApp Health : announces FDA 510(k) submission for SleepCheckRx | View printer-friendly version
ResApp has submitted a 510(k) premarket notification to the US FDA for SleepCheckRx
SleepCheckRx is a smartphone-only solution that uses clinically accurate algorithms to assess a patient's risk of obstructive ... |
| 14.09.2021 | ResApp Health : receives Advanced and Overseas R&D finding | View printer-friendly version
Brisbane, Australia, 14 September 2021 - ResApp Health Limited (ASX:RAP), a leading digital health company developing smartphone applications for the diagnosis and management of respiratory disease is pleased t... |
| 01.09.2021 | ResApp Health : ResAppDx receives regulatory approval in Indonesia | View printer-friendly version
Brisbane, Australia, 1 September 2021 - ResApp Health Limited (ASX:RAP), a leading digital health company developing smartphone applications for the diagnosis and management of respiratory disease, is pleased t... |
| 03.06.2021 | RESAPP HEALTH LIMITED
ResApp Health : Medgate extends European ResAppDx trial | View printer-friendly version
Brisbane, Australia, 3 June 2021 - ResApp Health Limited (ASX:RAP), a leading digital health company developing smartphone applications for the diagnosis and management of respiratory disease, today provides an... |
| 12.04.2021 | ResApp Health : secures firm commitments to raise $5.5 million | View printer-friendly version
Brisbane, Australia, 12 April 2021 - ResApp Health Limited (ASX:RAP), a leading digital health company developing smartphone applications for the diagnosis and management of respiratory disease, is pleased to a... |
| 12.04.2021 | RESAPP HEALTH LIMITED
ResApp Health : secures firm commitments to raise $5.5 million | View printer-friendly version
Brisbane, Australia, 12 April 2021 - ResApp Health Limited (ASX:RAP), a leading digital health company developing smartphone applications for the diagnosis and management of respiratory disease, is pleased to a... |
| 17.04.2019 | NuvoAir raises $3M to help patients monitor respiratory diseases with AI | With air quality not improving any time soon (hello pollution!), respiratory conditions are on the rise. This has created an opportunity for startups to employ smartphones to monitor respiratory diseases with apps and smart devices.
ResApp’... |
| 20.04.2016 | ResApp Nabs $12.5M For Smartphone App That Instantly Diagnose Respiratory Diseases | ResApp, a Australian-based digital health startup that has developed a smartphone app that can diagnose respiratory diseases based on the sound signatures of the coughs, announced it has raised $12.5 million in funding. The oversubscribed r... |
| 20.04.2016 | ResApp raises $9.74M for respiratory disease diagnostic app | Australia-based ResApp, a public company, has raised $9.74 million ($12.5 million Australian dollars) for its product, a smartphone-based system for diagnosing respiratory conditions. The company sold 62.5 million new ordinary shares at $0.... |
| 16.07.2015 | ‘Cough into this phone, please’: Perth startup’s diagnosis app could change the way respiratory problems are detected | Soon you’ll be able to self-diagnose that scratchy throat just by coughing into your smartphone, an Australian startup hopes.
The Perth-based ResApp can diagnose a range of respiratory problems, including pneumonia, bronchitis, pulmonary di... |
| - | A health firm says it has developed an app that can detect COVID-19 when an infected person coughs into their phone | More trials are needed before the app can be used by patients. Getty
New technology could help detect COVID-19 from the cough of an infected person, researchers have said.
The app uses machine-learning to analyze the sound of a person's cou... |
